MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
MCK stock logo

MCK

McKesson Corporation

$884.28
11.96
 (1.37%)
Exchange:  NYSE
Market Cap:  109.144B
Shares Outstanding:  87.935M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Distribution
   
CEO:  Brian S. Tyler
Full Time Employees:  44000
Address: 
6555 State Highway 161
Irving
TX
75039
US
Website:  https://www.mckesson.com
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/02/05 — 3 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue276,711,000308,951,000359,051,000
Gross Profit11,869,00012,202,00012,485,000
EBITDA5,735,0004,667,0005,251,000
Operating Income4,453,0003,927,0004,372,000
Net Income3,560,0003,002,0003,295,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets62,320,00067,443,00075,140,000
Total Liabilities63,810,00069,042,00076,834,000
Total Stockholders Equity-1,857,000-1,971,000-2,074,000
Total Debt7,295,0007,390,0007,390,000
Cash and Cash Equivalents4,678,0004,583,0005,691,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow5,159,0004,314,0006,085,000
Capital Expenditure-558,000-687,000-859,000
Free Cash Flow4,601,0003,627,0005,226,000
Net Income3,722,0003,002,0003,481,000
Net Change in Cash743,000-94,0001,371,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)539,888,997.292Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)562,233,507.780Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)551,306,400Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)5,089,197.266Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)5,299,825.048Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)5,196,822.009Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)8,245,054.084Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)8,691,499.240Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)8,473,174.566Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)15,793,598.878Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)16,447,252.199Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)16,127,596.940Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)66.150Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)67.850Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)64.360Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
308.951B  ?P/S
 (TTM)
: 
0.27
?Net Income
 (TTM)
: 
3.002B  ?P/E
 (TTM)
: 
24.59
?Enterprise Value
 (TTM)
: 
112.599B  ?EV/FCF
 (TTM)
: 
11.15
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0.09
?ROE
 (TTM)
: 
-2.45  ?ROIC
 (TTM)
: 
0.24
?Net Debt
 (TTM)
: 
8.475B  ?Debt/Equity
 (TTM)
: 
-6.64
?P/B
 (TTM)
: 
-82.23  ?Current Ratio
 (TTM)
: 
0.88

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
22.71Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates MCK intrinsic value between $397.98 – $587.94 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate MCK Intrinsic Value

Common questions about MCK valuation

Is McKesson Corporation (MCK) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for McKesson Corporation (MCK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is MCK a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MCK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is MCK’s P/E ratio?

You can see MCK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for MCK?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is MCK a good long-term investment?

Whether MCK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

MCK

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.37
MARKETSnap

Trading Metrics:

Open: 869.33   Previous Close: 872.32
Day Low: 866.79   Day High: 887.21
Year Low: 637   Year High: 999
Price Avg 50: 909.13   Price Avg 200: 800.08
Volume: 439579   Average Volume: 775159

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Is McKesson Stock Still A High-Conviction Compounder?
21-04-2026 12:26
Is McKesson Stock Still A High-Conviction Compounder?
McKesson to Sell Stake of Medical-Surgical Unit to Apollo
20-04-2026 08:58
McKesson to Sell Stake of Medical-Surgical Unit to Apollo
McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
20-04-2026 08:34
McKesson sells minority stake in surgical supplies unit to Apollo Funds for $1.25 billion
McKesson (MCK) Advances But Underperforms Market: Key Facts
08-04-2026 19:00
McKesson (MCK) Advances But Underperforms Market: Key Facts
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
07-04-2026 13:11
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
McKesson (MCK) Outperforms Broader Market: What You Need to Know
02-04-2026 19:01
McKesson (MCK) Outperforms Broader Market: What You Need to Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read